tiprankstipranks
Trending News
More News >
Suven Pharmaceuticals Ltd. (IN:SUVENPHAR)
:SUVENPHAR
India Market
Advertisement

Suven Pharmaceuticals Ltd. (SUVENPHAR) Stock Forecast & Price Target

Compare
2 Followers
See the Price Targets and Ratings of:

SUVENPHAR Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Suven
Pharmaceuticals Ltd.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

SUVENPHAR Stock 12 Month Forecast

There Are No Analyst Ratings for IN:SUVENPHAR In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

SUVENPHAR Financial Forecast

SUVENPHAR Earnings Forecast

Next quarter’s earnings estimate for SUVENPHAR is ₹1.55 with a range of ₹1.50 to ₹1.60. The previous quarter’s EPS was ₹1.55. SUVENPHAR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year SUVENPHAR has Preformed in-line its overall industry.
Next quarter’s earnings estimate for SUVENPHAR is ₹1.55 with a range of ₹1.50 to ₹1.60. The previous quarter’s EPS was ₹1.55. SUVENPHAR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year SUVENPHAR has Preformed in-line its overall industry.

SUVENPHAR Sales Forecast

Next quarter’s sales forecast for SUVENPHAR is ₹5.85B with a range of ₹5.50B to ₹6.58B. The previous quarter’s sales results were ₹5.49B. SUVENPHAR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year SUVENPHAR has Preformed in-line its overall industry.
Next quarter’s sales forecast for SUVENPHAR is ₹5.85B with a range of ₹5.50B to ₹6.58B. The previous quarter’s sales results were ₹5.49B. SUVENPHAR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year SUVENPHAR has Preformed in-line its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on IN:SUVENPHAR
TR | OpenAI - 4o
TR | OpenAI - 4o
₹954₹814
Hold
-8.65%
Downside
Reiterated
10/30/25
AI Generated ArticleAI Generated Article
Goldman Sachs Analyst forecast on IN:SUVENPHAR
Goldman Sachs
Goldman Sachs
₹1,350
Buy
51.50%
Upside
Initiated
04/08/25
Goldman Sachs Starts Suven Pharmaceuticals Ltd (SUVENPHA:IN) at BuyGoldman Sachs analyst Shyam Srinivasan initiates coverage on Suven Pharmaceuticals Ltd (SUVENPHA:IN) with a Buy rating and a price target of INR1,350.00.
Macquarie
₹1,500
Buy
68.33%
Upside
Reiterated
03/28/25
Macquarie Reiterates Outperform Rating on Suven Pharmaceuticals Ltd (SUVENPHA:IN)Macquarie analyst Kunal Dhamesha reiterated an Outperform rating and INR1,500.00 price target on Suven Pharmaceuticals Ltd (SUVENPHA:IN).
ICICI Securities Analyst forecast on IN:SUVENPHAR
ICICI Securities
ICICI Securities
₹1,400
Buy
57.11%
Upside
Initiated
03/25/25
ICICI Securities Starts Suven Pharmaceuticals Ltd (SUVENPHA:IN) at Buy (1)ICICI Securities analyst Abdulkader Puranwala initiates coverage on Suven Pharmaceuticals Ltd (SUVENPHA:IN) with a Buy (1) rating and a price target of INR1,400.00.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TR | OpenAI - 4o Analyst forecast on IN:SUVENPHAR
TR | OpenAI - 4o
TR | OpenAI - 4o
₹954₹814
Hold
-8.65%
Downside
Reiterated
10/30/25
AI Generated ArticleAI Generated Article
Goldman Sachs Analyst forecast on IN:SUVENPHAR
Goldman Sachs
Goldman Sachs
₹1,350
Buy
51.50%
Upside
Initiated
04/08/25
Goldman Sachs Starts Suven Pharmaceuticals Ltd (SUVENPHA:IN) at BuyGoldman Sachs analyst Shyam Srinivasan initiates coverage on Suven Pharmaceuticals Ltd (SUVENPHA:IN) with a Buy rating and a price target of INR1,350.00.
Macquarie
₹1,500
Buy
68.33%
Upside
Reiterated
03/28/25
Macquarie Reiterates Outperform Rating on Suven Pharmaceuticals Ltd (SUVENPHA:IN)Macquarie analyst Kunal Dhamesha reiterated an Outperform rating and INR1,500.00 price target on Suven Pharmaceuticals Ltd (SUVENPHA:IN).
ICICI Securities Analyst forecast on IN:SUVENPHAR
ICICI Securities
ICICI Securities
₹1,400
Buy
57.11%
Upside
Initiated
03/25/25
ICICI Securities Starts Suven Pharmaceuticals Ltd (SUVENPHA:IN) at Buy (1)ICICI Securities analyst Abdulkader Puranwala initiates coverage on Suven Pharmaceuticals Ltd (SUVENPHA:IN) with a Buy (1) rating and a price target of INR1,400.00.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Suven Pharmaceuticals Ltd.

1 Month
xxx
Success Rate
1/2 ratings generated profit
50%
Average Return
-0.50%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of -0.50% per trade.
3 Months
xxx
Success Rate
0/2 ratings generated profit
0%
Average Return
-13.05%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -13.05% per trade.
1 Year
Success Rate
0/2 ratings generated profit
0%
Average Return
-23.10%
reiterated a buy rating 7 months ago
Copying Kunal Dhamesha's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -23.10% per trade.
2 Years
xxx
Success Rate
0/2 ratings generated profit
0%
Average Return
-25.25%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -25.25% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SUVENPHAR Analyst Recommendation Trends

Rating
Mar 25
Apr 25
Jul 25
Aug 25
Sep 25
Strong Buy
0
0
0
0
0
Buy
3
4
3
1
0
Hold
0
0
7
8
10
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
3
4
10
9
10
In the current month, SUVENPHAR has received 0 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. SUVENPHAR average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

SUVENPHAR Stock Forecast FAQ

What is IN:SUVENPHAR’s average 12-month price target, according to analysts?
Currently, no data Available
What is IN:SUVENPHAR’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for IN:SUVENPHAR, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Suven Pharmaceuticals Ltd. a Buy, Sell or Hold?
      Currently, no data Available
      What is Suven Pharmaceuticals Ltd.’s share price target?
      Currently, no data Available
      What do analysts say about Suven Pharmaceuticals Ltd.?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Suven Pharmaceuticals Ltd.?
      To buy shares of IN:SUVENPHAR, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis